General News
Published September 8, 2020
Premera Blue Cross will be extending cost
share waivers for COVID-19 treatment through December 31, 2020. This means that
members will not pay a cost share requiring treatment for COVID-19. FDA-approved
diagnostic testing and the related provider visit cost share waivers are
extended through October 23, 2020 in compliance with Federal rules. All other
treatments and services including hospitalizations will be subject to the usual
benefits and cost shares. We will continue to evaluate guidance and the scope
of COVID-19 and adjust as needed.
This extension applies to all fully insured, individual, and self-funded groups who opted into the cost share waivers.
For more information regarding COVID-19 testing and treatment visit our producer FAQ or contact your Premera representative.